HC Wainwright Has Bearish Forecast for JANX FY2030 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at HC Wainwright decreased their FY2030 EPS estimates for Janux Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.97 per share for the year, down from their prior forecast of $1.06. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.70) per share.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

JANX has been the subject of several other reports. JonesTrading decreased their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. UBS Group downgraded shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. Piper Sandler reduced their price objective on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wedbush decreased their target price on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Finally, Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a report on Friday. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.58.

Janux Therapeutics Trading Up 3.5%

JANX opened at $16.41 on Tuesday. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -10.01 and a beta of 2.50. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34. The stock has a fifty day moving average price of $15.08 and a 200-day moving average price of $14.47.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently made changes to their positions in the stock. Nano Cap New Millennium Growth Fund L P purchased a new position in Janux Therapeutics in the 4th quarter worth $34,000. Versant Capital Management Inc grew its stake in Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Janux Therapeutics in the 4th quarter worth approximately $51,000. Osaic Holdings Inc. increased its holdings in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.